Merck starts phase 2b/3 trial for eye disease drug MK-8748

April 2, 2026 6:50 AM

Merck & Co. (NYSE: MRK) announced the initiation of a pivotal Phase 2b/3 trial evaluating MK-8748, an investigational bispecific antibody ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found